Ranbaxy Laboratories, Inc.

Jitendra Krishan Somani

Indu Bhushan

Himadri Sen

Om Dutt Tyagi

Sanjeev Sethi

A process for preparing cefuroxime axetil in substantially amorphous form comprises forming a mixture of crystalline cefuroxime axetil and at least one pharmaceutically acceptable excipient, and subjecting the mixture to milling for a period of time sufficient to convert the crystalline cefuroxime axetil to substantially amorphous form, i.e., the crystallinity is less than 5%. The amorphous cefuroxime axetil has a chemical purity of at least 95%. Desirably, the particles of the milled material are reduced to a size of less than 2.

Process for the preparation of cefuroxime axetil in an amorphous form

This invention relates to a process of mixing of crystalline cefuroxime axetil with amorphous cefuroxime axetil for the preparation of a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.

Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil

This invention relates to a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.

Bioavailable oral dosage form of cefuroxime axetil

A stable solid pharmaceutical composition in the form of tablets or capsules is disclosed including enalapril maleate as active ingredient and pharmaceutically acceptable excipients wherein at least one excipient is maleic acid or other edible desiccants.

Stable solid pharmaceutical compositions containing enalapril maleate

A process for preparing cefuroxime axetil in substantially amorphous form comprises forming a mixture of crystalline cefuroxime axetil and at least one pharmaceutically acceptable excipient, and subjecting the mixture to milling for a period of time sufficient to convert the crystalline cefuroxime axetil to substantially amorphous form, i.e., the crystallinity is less than 5%. The amorphous cefuroxime axetil has a chemical purity of at least 95%. Desirably, the particles of the milled material are reduced to a size of less than 2 .mu.m. The amorphous cefuroxime axetil prepared by this method may consist of R isomer, S isomer, or a racemic mixture of the R and S isomers.

Growing community of inventors

Gurgaon, India

Jitendra Krishan Somani